Back

ICON 3

Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial
Date of Publication:

August 17, 2002

Pubmed Link:
https://pubmed.ncbi.nlm.nih.gov/12241653/
Hypothesis:

Carbo/paclitaxel improves OS in women with epithelial ovarian cancer

Control Arm(s):

(1) Carboplatin AUC 5
- q3wks x6 cycles

(2) Cyclophosphamide 500mg/m2
Doxorubicin 50mg/m2
Cisplatin 50mg/m2
- q3wks x6 cycles

Experimental Arm(s):

Carboplatin AUC 5
Paclitaxel 175mg/m2 over 3hrs
- q3wk x6 cycles

Primary End Point:
OS
Inclusion Criteria:

Clinician certain that patient requires chemotherapy
Confirmed invasive epithelial ovarian cancer after surgery

Exclusion Criteria:

Prior chemoRT

Results:

Median f/u: 51 mos

Carbo/paclitaxel (n=610) vs (1) and (2) (total n=1364):

Median PFS: 17.3 vs 16.1 mos (NS)
Median OS: 36.1 vs 35.4 mos (NS)
Alopecia highest in (2) and carbo/paclitaxel (~75%)
Sensory neuropathy highest in carbo/paclitaxel (~20%)

Conclusions:

Single agent carboplatin and (2) are as effective as carbo/paclitaxel as first line treatment for women with epithelial ovarian cancer. Side effect profile favors single agent carbo.

Reviewer:
Olga T. Filippova